Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

NiKang Therapeutics And AVEO Oncology Announce Clinical Trial Collaboration And Supply Agreement To Evaluate Combination Of NKT2152, A HIF2α Inhibitor, And FOTIVDA (tivozanib) For The Treatment Of Advanced Clear Cell Renal Cell Carcinoma

- Phase 2 Clinical Trial Targeted to Commence in 2022 - NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients

AVEO